FGF23 blockade coming to clinical practice

Kidney Int. 2018 Nov;94(5):846-848. doi: 10.1016/j.kint.2018.08.022.

Authors

Francesco Emma¹, Dieter Haffner²

Affiliations

¹ Department of Pediatric Subspecialties, Division of Nephrology, Bambino Gesù Children's Hospital, Rome, Italy. Electronic address: francesco.emma@opbg.net.
² Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany. Electronic address: Haffner.Dieter@mh-hannover.de.

PMID: 30348298
DOI: 10.1016/j.kint.2018.08.022

No abstract available

Keywords: FGF23; bone; rickets.

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Familial Hypophosphatemic Rickets / drug therapy*
Familial Hypophosphatemic Rickets / etiology
Fibroblast Growth Factor-23
Fibroblast Growth Factors / antagonists & inhibitors*
Fibroblast Growth Factors / physiology
Humans

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
FGF23 protein, human
Fibroblast Growth Factors
Fibroblast Growth Factor-23
burosumab